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ABSTRACT
Neuroblastoma is a predominantly p53 wild-type (wt) tumour and MDM2-p53 
antagonists offer a novel therapeutic strategy for neuroblastoma patients. RG7388 
(Roche) is currently undergoing early phase clinical evaluation in adults. This 
study assessed the efficacy of RG7388 as a single-agent and in combination with 
chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma 
cell lines. RG7388 GI50 concentrations were determined in 21 p53-wt and mutant 
neuroblastoma cell lines of varying MYCN, MDM2 and p14ARF status, together with 
MYCN-regulatable Tet21N cells. The primary determinant of response was the presence 
of wt p53, and overall there was a >200-fold difference in RG7388 GI50 concentrations 
for p53-wt versus mutant cell lines. Tet21N MYCN+ cells were significantly more 
sensitive to RG7388 compared with MYCN- cells. Using median-effect analysis in 5 
p53-wt neuroblastoma cell lines, selected combinations of RG7388 with cisplatin, 
doxorubicin, topotecan, temozolomide and busulfan were synergistic. Furthermore, 
combination treatments led to increased apoptosis, as evident by higher caspase-3/7 
activity compared to either agent alone. These data show that RG7388 is highly potent 
against p53-wt neuroblastoma cells, and strongly supports its further evaluation as 
a novel therapy for patients with high-risk neuroblastoma and wt p53 to potentially 
improve survival and/or reduce toxicity.
INTRODUCTION
The p53 protein plays a central role in tumour 
suppression, by regulating the expression of numerous 
downstream target genes involved in cellular processes 
such as apoptosis, cell cycle arrest, differentiation and 
senescence. Under normal cellular conditions, p53 is 
maintained at low levels due a tightly regulated negative 
feedback loop involving the critical negative regulator, 
MDM2. MDM2 is an E3 ubiquitin ligase, induced in 
response to p53 activation to directly bind p53 and 
inhibit its transcriptional activity, as well as promote the 
nuclear export and targeting of p53 for ubiquitin mediated 
proteasome degradation. p14ARF is a tumour suppressor 
and a negative regulator of MDM2 (reviewed by [1]). 
The importance of p53 in human cancer is emphasised 
by observations that p53 is mutated in up to half of all 
malignancies, whilst aberrant upstream or downstream 
p53 pathways, including MDM2 amplification and p14ARF 
inactivation are common events in p53 wild-type (wt) 
cancers [2]. 
MDM2-p53 binding antagonists are a novel class 
of anti-cancer therapeutics currently in early clinical 
development, which act by disrupting the interaction 
between p53 and MDM2 to non-genotoxically activate 
wt p53. Hoffmann-La Roche were the first to report 
potent and selective small molecule MDM2-p53 binding 
antagonists, the cis-imidazoline (Nutlin) compound series 
[3]. To date, Nutlin-3 has been shown to stabilise p53 
and activate the p53 pathway, inducing cell cycle arrest, 
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apoptosis, differentiation and/or senescence, in several p53 
wt pre-clinical cancer models. The lead cis-imidazoline, 
RG7112, was subsequently the first of its class to 
enter clinical trials and despite demonstrating proof-
of-mechanism in adult MDM2-amplified liposarcoma 
patients [4], results from several Phase I trials indicated 
highly variable bioavailability, a poor tolerability to daily 
oral administration and thrombocytopenia as a dose-
limiting toxicity [5]. Subsequently, RG7388, a pyrrolidine 
and second generation MDM2-p53 antagonist from 
Hoffman-La Roche with enhanced potency, selectivity and 
bioavailability, and available in both oral and intravenous 
(IV) formulations has been developed [6]. To overcome 
tolerability issues with daily administration, intermittent 
schedules of RG7388, which may enable the bone 
marrow to recover have advanced to clinical evaluation 
in adults alone and in combination (www.clinicaltrials.
gov; NCT01462175; NCT01773408; NCT02098967) [7, 
8]. RG7388 is anticipated to enter paediatric early phase 
trials in the near future.
Neuroblastoma is an embryonal malignancy of 
the developing neural crest accounting for 8-10% of 
all paediatric cancers but 15% of childhood cancer 
mortality [9]. Over 50% of patients present with high-
risk metastatic disease at the time of diagnosis. Despite 
an initial response to intensive multimodal therapy, 
relapse with chemoresistant disease is common and can 
rarely be salvaged. MYCN gene amplification, found in 
50% of high-risk patients, is associated with rapid tumour 
progression and a poor prognosis (reviewed by [10]). The 
overall long-term survival of high-risk patients currently 
remains less than 50%, with survivors often having 
long-term toxicities as a consequence of the intensive 
chemotherapy. Thus there is a continuing need to identify 
novel and less toxic therapies to improve survival of this 
subset of patients. 
In neuroblastoma p53 mutations are rare, even at 
relapse (< 15%), and inactivation of the p53/MDM2/p14ARF 
pathway in relapsed neuroblastoma is predominantly due 
to lesions upstream of p53, such as MDM2 amplification 
and p14ARF aberrations [11]. Non-genotoxic activation 
of wt p53 using MDM2-p53 antagonists offers a novel 
therapeutic strategy for neuroblastoma treatment. 
Acquisition of resistance through de novo mutations 
following continuous exposure to Nutlin-3 have however 
been reported in vitro, and may limit the usefulness of 
MDM2-p53 antagonists as single-agent therapy [12]. This 
provides a rationale for using MDM2-p53 antagonists to 
improve the therapeutic index of current chemotherapy 
regimens, to enhance tumour killing without increasing 
toxicity whilst minimising the development of resistance. 
Studies to date have demonstrated the efficacy of Nutlin-3 
in pre-clinical neuroblastoma models alone and in 
combination with cisplatin, camptothecin and bleomycin, 
and with targeted agents including bevacizumab and 
seliciclib (reviewed by [13]). However, the pre-clinical 
efficacy of the most advanced clinical candidate, RG7388, 
has yet to be evaluated in paediatric cancers, including 
neuroblastoma. 
Using a panel of neuroblastoma cell lines, this study 
assessed the efficacy of RG7388 as a single agent, and in 
combination with chemotherapies routinely used to treat 
neuroblastoma, namely, cisplatin, doxorubicin, topotecan, 
temozolomide and busulfan. The overall aim was to 
provide pre-clinical data to support the clinical evaluation 
of RG7388 alone and/or in combination with conventional 
chemotherapy in patients with neuroblastoma to improve 
outcome and reduce toxicity.
RESULTS
RG7388 is highly potent in p53 wt neuroblastoma 
cell lines
The concentration of RG7388 required to inhibit 
growth by 50% (GI50) was determined using XTT cell 
proliferation assays in a panel of neuroblastoma cell lines, 
including 5 p53 mutant and 16 p53 wt cell lines of varying 
MYCN, MDM2 and p14ARF status, together with the p53 wt 
MYCN-regulatable SHEP Tet21N cells (Table 1, Figure 
1A, Supplementary Figure 1A). The panel included 
2 isogenic paired p53 wt and mutant cell lines, IMR32 
and IMR/KAT100, and NGP, N_N20R1 and N_M5R1. 
p53 wt, MDM2 amplified human osteosarcoma SJSA-1 
cells, previously shown to be sensitive to RG7388 and 
extensively used in the pre-clinical evaluation of several 
classes of MDM2-p53 antagonists to date, were used as a 
positive control [6, 8, 14-17] (Table 1). Consistent with the 
mechanism of action of MDM2-p53 antagonists, p53 wt 
neuroblastoma cell lines were significantly more sensitive 
to RG7388 compared to p53 mutant cell lines (P < 0.0001, 
Mann-Whitney test). Overall, all 16 neuroblastoma cell 
lines with wt p53 had nanomolar range GI50 values 
(range 14.8-140.3 nM; 68.2 (mean) ± 43.3 (SD) nM) of 
comparable sensitivity to SJSA-1 cells. In contrast, all 5 
p53 mutant cell lines had GI50 values greater than 10 µM 
(range 10.1-16.9 µM; 14.6 (mean) ± 2.7 (SD) µM) (Table 
1 and Figure 1A), representing > 200-fold differential 
between the average GI50 concentrations of p53 wt versus 
p53 mutant cell lines. Comparisons of GI50 concentrations 
between paired isogenic p53 wt and mutant neuroblastoma 
cell lines, demonstrated a 252-fold differential between 
IMR32 and IMR/KAT100, and a 406-fold and 384-fold 
differential between NGP and N_N20R1, and NGP and 
N_M5R1, respectively. 
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Figure 1: (A) Sensitivity of a panel of neuroblastoma cell lines of varying MYCN, MDM2, p53 and p14ARF status to RG7388 
treatment for 72 hours. p53 wt cell lines are significantly more sensitive to RG7388 treatment versus p53 mutant cell lines (Mann Whitney 
test, P < 0.0001), and Tet21N MYCN+ cells are significantly more sensitive to RG7388 compared with Tet21N MYCN- cells (paired t test, 
P < 0.005). Data are shown as the average of at least 3 independent experiments and error bars represent SEM. (B) The sensitivity of Tet21N 
MYCN+ and MYCN- cells to MDM2 antagonists, Nutlin-3a, NDD0005 and MI-63. Tet21N MYCN+ cells are significantly more sensitive 
to Nutlin-3a (paired t test, P < 0.05), NDD0005 (paired t test, P < 0.005) and MI-63 (paired t test, P < 0.05) treatment for 72 hours compared 
with Tet21N MYCN- cells. Data shown are the average of at least 3 independent experiments and error bars represent SEM. (C) RG7388 
treatment leads to stabilisation of p53 and upregulation of p53 targets, MDM2, p21 and PUMA in p53 wt but not p53 mutant neuroblastoma 
cell lines. Western analysis for activation of the p53 pathway in the panel of neuroblastoma cell lines and the p53 wt MYCN regulatable 
SHEP Tet21N cells in response to treatment for 6 hours with 1× and 10× their respective RG7388 GI50 concentrations. p53 mutant cell lines 
are represented in bold font and MDM2 amplified cell lines are represented in italics. D, DMSO treated control cells.
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MYCN, MDM2 and p14ARF status and sensitivity 
to RG7388
MYCN, p14ARF and MDM2 status have previously 
been linked to sensitivity to MDM2-p53 antagonists [18, 
19]. In the isogenic Tet21N system, Tet21N MYCN+ 
cells were significantly more sensitive to RG7388 
compared with Tet21N MYCN- cells (P < 0.005, paired 
t test, Figure 1A). Further studies found that Tet21N 
MYCN+ cells were also significantly more sensitive to 
other classes of MDM2-p53 antagonists, namely Nutlin-
3a (cis-imidazoline) (P < 0.05, paired t test), NDD0005 
(isoindolinone) (P < 0.005, paired t test) and MI-63 (spiro-
Table 1: GI50 concentrations for RG7388 in control osteosarcoma SJSA-1 cells and a panel of 21 neuroblastoma cell 
lines of varying p53, MYCN, MDM2, and p14ARF status, and the MYCN-regulatable Tet21N cells. Data represents the 
mean of at least 3 independent experiments ± SEM.
Cell Line p53 Status MYCN Status MDM2 Status p14
ARF Deln/
Meth Cell Type RG7388 (nM)
SJSA-1 Wt Non-Amp Amp  - 23.7 ± 1.5
SKNAS Mut Non-Amp Non-Amp  S  10133 ± 240.8
SKNBe2C Mut Amp Non-Amp  I  14040.8 ± 656.7
IMR/KAT100 Mut Amp Non-Amp  N  16291 ± 470.5
N_N20R1 Mut Amp Amp  N  16851.3 ± 161.9
N_M5R1 Mut Amp Amp  N  15926.7 ± 307.7
SHSY5Y Wt Non-Amp Non-Amp  N 40.0 ± 3.9
NB69 Wt Non-Amp Non-Amp  N>S 17.5 ± 0.4
NBLS Wt Non-Amp Non-Amp  S 41.6 ± 1.6
SKNRA Wt Non-Amp Non-Amp  S 140.3 ± 14.7
SJNB1 Wt Non-Amp Non-Amp  S>N 136.2 ± 19.9
IMR32 Wt Amp Non-Amp  N 64.7 ± 6.0
LAN5 Wt Amp Non-Amp  N 68.0 ± 1.9
NBLW Wt Amp Non-Amp  N>S 14.8 ± 0.3
NGP Wt Amp Amp  N 41.5 ± 2.8
NB1691 Wt Amp Amp  N 41.0 ± 4.1
TR-14 Wt Amp Amp  N 48.2 ± 0.8
LS Wt Amp Amp  N 56.3 ± 4.6
LAN6 Wt Non-Amp Non-Amp Deleted N 80.0 ± 9.1
SHEP Wt Non-Amp Non-Amp Deleted S 113.8 ± 33.9
GIMEN Wt Non-Amp Non-Amp Methylated S>N 86.1 ± 7.3
Per-108 Wt Amp Non-Amp Methylated N 53.7 ± 3.7
Tet21N MYCN- Wt Non-Amp Non-Amp Deleted S 295.2 ± 39.7
Tet21N MYCN+ Wt Non-Amp Non-Amp Deleted S 44.1 ± 8.2
p14ARF Deln/Meth, p14ARF deleted/methylated; Wt, wild type; Mut, mutant; Non-Amp, non-amplified; Amp, amplified; N, 
neurite bearing (N-type); S, substrate adherent (S-type); I, intermediate (I-type)
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oxindole) (P < 0.05, paired t test), compared with Tet21N 
MYCN- cells (Figure 1B). Sensitivity of the present panel 
of neuroblastoma cell lines to RG7388 was analysed in 
relation to their MYCN, p14ARF and MDM2 status (Table 
1 and Supplementary Figure 1B-E). The present panel 
included 8 MYCN amplified and 8 non-MYCN amplified 
p53 wt neuroblastoma cell lines (Table 1), and there was 
a non-significant trend for MYCN amplified cell lines to 
be more sensitive to RG7388 (P = 0.087, Welch t test, 
Supplementary Figure 1B). 
Four out of 16 of the panel had p14ARF aberrations 
and 4/16 had non-syntenic amplification of MDM2 and 
MYCN (Table 1 and Supplementary Figure 1A). Of note, 
p14ARF and MDM2 abnormalities were mutually exclusive. 
There was a non-significant trend for p14ARF aberrant cell 
lines to be more resistant to RG7388 (P = 0.187, Welch 
t test, Supplementary Figure 1C). Similarly, there was a 
non-significant trend for MDM2/MYCN co-amplified cell 
lines to be more sensitive to RG7388 versus cell lines 
which were not MDM2/MYCN co-amplified (P = 0.074, 
Welch t test, Supplementary Figure 1D). No difference in 
sensitivity to RG7388 was found between MDM2/MYCN 
co-amplified versus MYCN amplified (P = 0.797, Welch t 
test, Supplementary Figure 1E).
Functional activation of the p53 pathway in p53 
wt neuroblastoma cell lines in response to RG7388 
treatment
In the same panel of 21 neuroblastoma cell lines 
and the Tet21N system, functional activation of the 
p53 pathway in response to treatment for 6 hours with 
RG7388 at 1× and 10× their respective GI50 concentrations 
(Table 1) were assessed by Western blotting (Figure 1C). 
Stabilisation of p53, and induction of p53 targets, MDM2, 
p21WAF1 and PUMA were observed in all 16 p53 wt cell 
lines and Tet21N MYCN+ and MYCN- cells (Figure 
1C), and in some cases this occurred in a concentration-
dependent manner. Tet21N MYCN+ cells had higher basal 
p53 levels, as previously reported [20], and in response 
to RG7388 treatment exhibited higher levels of p53 
stabilisation and had higher levels of MDM2 and PUMA 
compared with Tet21N MYCN- cells (Figure 1C). As 
expected, no induction of p53 or p53 targets was observed 
in p53 mutant neuroblastoma cell lines. All p53 mutant 
cell lines demonstrated a decrease in p53 expression 
in response to treatment with 10× their respective 
GI50 concentrations of RG7388, which is most likely 
attributable to the very high concentrations of RG7388 
affecting cell viability due to off-target effects (Figure 1C). 
RG7388 induces cell cycle arrest and apoptosis in 
p53 wt neuroblastoma cell lines 
From the original panel of cell lines assessed above, 
8 p53 wt neuroblastoma cell lines (non-MYCN amplified 
SHSY5Y & SKNRA; MYCN amplified IMR32 & LAN5; 
MDM2 and MYCN co-amplified NGP & NB1691; 
p14ARF methylated Per-108 & GIMEN) and Tet21N 
cells were analysed for cell cycle phase distribution and 
induction of apoptosis in response to RG7388 (Figure 2 
and Supplementary Table 1). Cells were treated for 24 
hours with 1×, 10×, 50× and 100× their respective GI50 
concentrations of RG7388 (Table 1) and analysed using 
flow cytometry. An increase in the percentage of sub-G1 
events, as a surrogate marker of apoptosis, was observed 
in all cell lines in response to one or more concentrations 
of RG7388. Overall, the accumulation of events in sub-G1 
phase occurred in a concentration-dependent manner 
(Figure 2A and Supplementary Table 1). The G1:S ratio 
was calculated as an indicator of G1 cell cycle arrest, and 
with the exception of MYCN amplified LAN5 and IMR32 
cells, all other cell lines including Tet21N cells in the 
presence and absence of MYCN, demonstrated at least a 
2-fold increase in G1:S ratio in response to treatment with 
at least one or more concentrations of RG7388 (Figure 
2B and Supplementary Table 1). In line with the role of 
MYCN in driving proliferation, switching off MYCN in 
the Tet21N system led to an increase in baseline G1:S ratio 
(MYCN+, 4.2 ± 0.8 versus MYCN-, 17.6 ± 5.3) (Figure 
2B and Supplementary Table 1). Finally, treatment with ≥ 
10× GI50 concentrations of RG7388 led to an accumulation 
of cells in G2/M phase in NGP, NB1691 and GIMEN cells 
(Figure 2A and Supplementary Table 1). 
RG7388 induced apoptosis was also assessed by 
Caspase 3/7 assays in the 8 cell lines following treatment 
for 24 hours with 1× and 10× their respective RG7388 GI50 
concentrations (Figure 2C). With the exception of SKNRA 
and Tet21N cells, all remaining p53 wt neuroblastoma 
cell lines exhibited a concentration-dependent increase 
in caspase 3/7 activity in response to RG7388 (Figure 
2C). In Tet21N cells, MYCN+ cells had consistently 
higher caspase 3/7 activity compared with MYCN- cells 
(data not shown). In the majority of cell lines, increases 
in caspase 3/7 activity (Figure 2C) were consistent 
with the accumulation of sub-G1 events (Figure 2A and 
Supplementary Table 1), although caspase 3/7 activity is a 
more sensitive and specific indicator of apoptosis. 
RG7388 synergises with chemotherapies currently 
used to treat neuroblastoma
The current treatment of high-risk neuroblastoma 
involves combinations of different chemotherapies, 
including cisplatin, doxorubicin, topotecan, temozolomide 
and busulfan. Median-effect analysis was used to 
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Figure 2: RG7388 treatment induces cell cycle arrest and/or apoptosis in p53 wt neuroblastoma cell lines. Sub-G1 and 
cell cycle phase distribution (A) and G1:S ratios (B) of 8 p53 wt neuroblastoma cell lines and the MYCN regulatable SHEP Tet21N cells 
treated for 24 hours with 1×, 10×, 50× or 100× their respective RG7388 GI50 concentrations. (C) Caspase 3/7 activity in the same panel of 
cell lines in response to 24 hours treatment with 1× or 10× their respective RG7388 GI50 concentrations or an equal volume of DMSO. Data 
are expressed as fold change relative to DMSO control, and are shown as the average of at least 3 independent experiments and error bars 
represent SEM. D, DMSO treated control cells; MYCN+, Tet21N MYCN+; MYCN-, Tet21N MYCN-.
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determine whether RG7388 can synergise with these 
chemotherapies in non-MYCN amplified SHSY5Y, MYCN 
amplified LAN5, and MDM2 and MYCN co-amplified 
NGP, LS and NB1691 p53 wt neuroblastoma cell lines. 
With the exception of LAN5 cells which were established 
at diagnosis, all other cell lines were established post-
treatment or at relapse. As part of median-effect analysis, 
the sensitivity of these p53 wt cell lines to 72 hours 
exposure to RG7388 and the above chemotherapies were 
determined. GI50 concentrations for RG7388 and the 
chemotherapies are shown in Tables 1 and 2, respectively. 
The sensitivity of the neuroblastoma cell lines in 
response to treatment with the tested chemotherapies 
alone demonstrated no obvious differences in GI50 
concentrations across the cell lines to cisplatin or 
topotecan. LAN5 and NGP cells were more sensitive 
to doxorubicin compared to SHSY5Y, LS and NB1691 
cells. Consistent with overexpression of methylguanine-
DNA methyltransferase (MGMT), a known mechanism of 
temozolomide resistance, NGP cells which lack MGMT 
Table 2: GI50 concentrations for chemotherapy agents, and the CI values for RG7388 in combination with cisplatin, 
doxorubicin, topotecan, temozolomide or busulfan in p53 wt SHSY5Y, NGP and LAN5 neuroblastoma cells. GI50 
concentrations are shown as the mean of at least 3 independent experiments ± SEM. RG7388 was combined with chemotherapy at the 
indicated fixed 1:1 ratios relative to their respective GI50 concentrations. CI values were calculated for each constant ratio combination and 
at effect levels ED50, ED75 and ED90 from the average of at least 3 independent experiments. CI Ave ED50-90 represents the average of CI 
values at effect levels ED50, ED75 and ED90. CI range: < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 
moderate synergism; 0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 
antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism.
Cell Line Chemotherapy GI50
CI
CI
ED50
CI
ED75
CI
ED90
CI
Ave 
ED50-90
× GI50
0.125 0.25 0.5 1 2 4
SHSY5Y1
Cisplatin 0.7 ± 0.1 µM ND 0.8 0.8 0.8 1 1 0.8 0.9 0.9 0.9
Doxorubicin 30.7 ± 2.7 nM ND 0.9 0.8 0.8 0.6 0.4 0.8 0.7 0.6 0.7
Topotecan 9.5 ± 0.2 nM ND 1.1 0.9 0.7 0.8 1.2 0.9 0.9 0.9 0.9
Temozolomide 331.5 ± 10.2 µM ND 0.5 0.6 0.8 1.1 1.7 0.7 0.9 1.2 0.9
Busulfan 26.21 ± 4.8 µM ND 0.7 0.7 0.9 1.3 1.3 0.8 1 1.3 1
NGP2
Cisplatin 1.1 ± 0.1 µM ND 0.9 1 1 0.8 0.5 1 0.9 0.7 0.9
Doxorubicin 9.6 ± 0.9 nM ND 0.6 0.6 0.5 0.5 0.8 0.5 0.5 0.6 0.5
Topotecan 9.9 ± 0.3 nM ND 0.8 0.7 0.3 0.4 0.8 0.6 0.5 0.5 0.6
Temozolomide 16.4 ± 3.7 µM ND 0.4 0.5 0.6 0.8 1.5 0.5 0.6 0.8 0.6
Busulfan 59.3 ± 3.1 µM ND 0.5 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.4
LAN51
Cisplatin 0.5 ± 0.1 µM ND 0.9 0.9 0.9 1 1.5 0.9 1 1.1 1
Doxorubicin 11.7 ± 0.6 nM ND 0.8 0.7 0.6 0.9 1.8 0.7 0.8 1 0.8
Topotecan 8.1 ± 0.7 nM ND 1.1 1 0.6 0.8 1.3 0.9 0.9 1 0.9
Temozolomide 174.3 ± 13.3 µM ND 0.4 0.6 0.9 1.2 2 0.6 0.8 1 0.8
Busulfan 66.0 ± 2.5 µM ND 0.6 0.8 0.9 1 0.9 0.8 0.8 0.9 0.8
LS1
Cisplatin 1.2 ± 0.3 µM ND 0.8 1 0.9 0.8 0.8 0.8 0.8 0.8 0.8
Doxorubicin 42.4 ± 5.9 nM ND 0.8 0.7 0.9 0.9 < 0.1 1 0.5 0.3 0.6
Topotecan 9.0 ± 0.3 nM ND 0.6 0.5 0.6 0.8 0.6 0.6 0.6 0.6 0.6
Temozolomide 525.6 ± 21.5 µM 1.6 1 0.7 1 1.2  ND 1.1 1 1 1
Busulfan 185.9 ± 8.8 µM ND 0.5 0.7 0.9 1 0.6 0.6 0.7 0.8 0.7
NB16911
Cisplatin 2.3 ± 0.1 µM ND 1.1 1.3 1.3 0.7 0.2 1.1 0.8 0.6 0.8
Doxorubicin 23.4 ± 2.6 nM ND 1 1.1 1.3 0.9 0.3 1.1 0.8 0.7 0.9
Topotecan 8.1 ± 0.2 nM ND 0.7 0.8 1 0.9 0.2 0.9 0.7 0.6 0.7
Temozolomide 868.1 ± 10.8 µM 1.1 1 0.9 0.6 0.4 ND 0.8 0.6 0.5 0.6
Busulfan 693.4 ± 38.6 µM 0.7 1 1 0.7 < 0.1 ND 0.9 0.4 0.2 0.5
1 high MGMT expression; 2 low MGMT expression (see supplementary Figure 1A); ND, not determined
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Figure 3: RG7388 synergises with cytotoxic chemotherapies in neuroblastoma cell lines. (A) Growth inhibition curves of 
p53 wt NGP cells exposed to RG7388 and chemotherapy agents (cisplatin, doxorubicin, topotecan, temozolomide and busulfan) alone, and 
in combination at constant 1:1 ratios of 0.25×, 0.5×, 1× , 2× and 4× their respective GI50 concentrations for 72 hours. Data are shown as the 
average of at least 3 independent experiments and error bars represent SEM. (B) CI values of RG7388 in combination with chemotherapy 
agents at 1× their respective GI50 concentrations and (C) the average of CI values of RG7388 in combination with chemotherapy agents 
at effect levels ED50, ED70 and ED90 in p53 wt SHSY5Y, NGP, LAN5, LS and NB1691 neuroblastoma cell lines. RG, RG7388; Cisplatin, 
CDDP; doxorubicin, DOX; topotecan, TOPO; temozolomide, TMZ; busulfan, BU.
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Figure 4: Combinations of RG7388 with temozolomide or busulfan leads to increased apoptosis in p53 wt neuroblastoma 
cells. p53 wt SHSY5Y, NGP and LAN5 cells were treated with their respective GI50 concentrations of RG7388 and chemotherapy agent 
alone, and in combination, and assessed at 72 hours post-treatment by (A) light-microscopy for morphological appearance and Western 
analysis for functional p53 pathway activation and (B) flow cytometry for sub-G1 and cell cycle phase distribution, and at 24 hours post-
treatment for (C) caspase 3/7 activity as an indicator of apoptosis. Caspase 3/7 activity is represented as fold change relative to solvent 
control. CON, solvent control; RG, RG7388; TMZ, Temozolomide; BU, busulfan. Data are shown as the average of at least 3 independent 
experiments and error bars represent SEM.
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expression were the most sensitive to temozolomide 
(Supplementary Figure 1A). NB1691 cells were the most 
resistant to both temozolomide and busulfan. 
For combination studies, cells were treated for 
72 hours with RG7388 and chemotherapies alone, and 
in combination at 5 equipotent concentrations between 
0.125× and 4× their respective GI50 concentrations 
depending on the cell line and chemotherapy agent (Table 
1 and 2). At least one or more of the in vitro RG7388 
and chemotherapy concentrations tested were within 
previously observed clinically achievable peak plasma 
drug concentrations. Combination treatment in all cases 
led to greater growth inhibition compared to either 
treatment alone (Figure 3A and Supplementary Figures 2 
& 3). The data were then analysed to determine whether 
the observed greater growth inhibition was additive or 
synergistic using median-effect analysis, which enables 
the quantitative evaluation of drug interactions based on 
the CI value. CI values were computed for each constant 
ratio combination and at estimated effect levels of ED50, 
ED75 and ED90 (Table 2 and Figure 3B & C). Overall, 
across all cell lines and chemotherapies, CI values varied 
with the effect level, therefore the average of CI values 
at ED50, ED75 and ED90 was also determined (Table 2 and 
Figure 3C). The majority of RG7388 and chemotherapy 
combinations at the GI50 concentrations ranged from 
slightly synergistic to synergistic (Figure 3B). The latter 
was also true when the average CI values at ED50, ED75 
and ED90 was used to evaluate the interaction (Figure 
3C). Taken together, cisplatin demonstrated the least 
degree of synergy with RG7388, whilst the remaining 
chemotherapies demonstrated comparable synergy with 
RG7388 (Table 2 and Figure 3B & C). With the exception 
of cisplatin, the most synergistic interactions between 
RG7388 and chemotherapy were observed in p53 wt, 
MDM2 and MYCN co-amplified NGP cells (Table 2 and 
Figure 3). This observation did not however extend to two 
additional MDM2 and MYCN co-amplified cell lines, LS 
and NB1691 (Table 2, Figure 3B & C and Supplementary 
Figure 3). RG7388 in combination with cisplatin and 
doxorubicin at their respective GI50 concentrations showed 
moderate antagonism in the NB1691 cells, but this was not 
observed when the average of CI values at ED50, ED75 and 
ED90 were taken into account (Table 2 and Figure 3B & C).
RG7388 in combination with chemotherapies 
leads to increased apoptosis 
Functional evaluation of RG7388 in combination 
with cisplatin, doxorubicin, topotecan, temozolomide 
and busulfan was performed in p53 wt SHSY5Y, NGP 
and LAN5 cells. Cells were treated with their respective 
GI50 concentrations for RG7388 and the chemotherapy 
agent alone, and in combination, and then assessed by 
light microscopy for morphological appearance, Western 
analysis for p53 pathway activation and flow cytometry 
for sub-G1 and cell cycle phase distribution at 72 hours 
post-treatment (Figure 4A & B and Supplementary Figure 
4A & B). In addition, cells were also assessed for caspase 
3/7 activity as an indicator of apoptosis at 24 hours 
post-treatment (Figure 4C and Supplementary Figure 
4C). Overall, for all combination treatments, there was 
an increase in the number of detached cells compared 
to vehicle control and either treatment alone (Figure 
4A and Supplementary Figure 4A). Western analysis 
demonstrated that treatment of p53 wt neuroblastoma 
cells with RG7388 and chemotherapy agents alone and 
in combination led to p53 stabilisation and activation of 
the p53 pathway (Figure 4A and Supplementary Figure 
4A). Furthermore, combination treatment in almost all 
cases induced greater levels of p53 stabilisation compared 
to the chemotherapy agent alone, and in some cases this 
was also greater than those induced by RG7388 alone. In 
response to treatment with GI50 concentrations of RG7388 
for 72 hours, SHSY5Y and LAN5 cells demonstrated an 
increase in both sub-G1 events and G1:S ratios, indicative 
of induction of apoptosis and a G1 cell cycle arrest, 
respectively (Figure 4B and Supplementary Figure 4B). In 
contrast, NGP cells only exhibited an increase in G1:S ratio 
(Figure 4B and Supplementary Figure 4B). Overall, at GI50 
concentrations, RG7388 was more potent than the tested 
chemotherapy agents at consistently inducing a cell cycle 
arrest in SHSY5Y, NGP and LAN5 cells. Assessment of 
caspase 3/7 activity as a marker of apoptosis demonstrated 
that GI50 concentrations of RG7388 or chemotherapy agent 
alone led to an increase in activity levels in SHSY5Y 
and LAN5 cells (Figure 4C and Supplementary Figure 
4C), however, only GI50 concentrations of busulfan and 
topotecan led to an increase in activity levels in NGP cells. 
Overall, combination treatments led to greater caspase 3/7 
activity in p53 wt neuroblastoma cells compared to vehicle 
control and single treatment alone, suggesting enhanced 
tumour cell killing (Figure 4C and Supplementary Figure 
4C). In addition, in the majority of cases, increases in 
caspase 3/7 activity at 24 hours post-treatment (Figure 4C 
and Supplementary Figure 4C) were consistent with the 
accumulation of sub-G1 events 72 hours post-treatment 
(Figure 4B and Supplementary Figure 4B). 
DISCUSSION
Chemotherapy remains an essential component 
of multimodal cancer treatment, but can result in severe 
short and long-term toxicity. In the modern era of cancer 
therapeutics there is a drive towards the identification and 
use of targeted agents to enhance cancer specific killing 
while reducing toxicity. The use of MDM2-p53 antagonists 
represents a potential novel therapeutic strategy in 
neuroblastoma, where the incidence of p53 mutations is 
much lower in comparison to adult malignancies and p53 
mutations are rare even at relapse (reviewed by [13]). This 
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study demonstrates for the first time the highly selective 
and potent in vitro anti-tumour activity of RG7388 as a 
single agent in p53 wt neuroblastoma of varying MYCN, 
MDM2 and p14ARF genetic status, resulting in p53 
stabilisation and activation of the p53 pathway. 
Within the present panel of p53 wt neuroblastoma 
cell lines, the highest RG7388 GI50 concentrations (≥ 
80 nM) were obtained in MYCN non-amplified cell 
lines of which 4/5 cell lines (SKNRA, SJNB1, SHEP 
and GIMEN) comprise predominantly S-type (substrate 
adherent) cells [21] and 3 cell lines (SHEP, GIMEN and 
LAN6) have p14ARF aberrations [22]. These observations 
are consistent with previous studies showing that MYCN 
sensitises neuroblastoma cell lines to MDM2-p53 
antagonists, Nutlin-3 and MI-63 [18], and p14ARF silencing 
leads to resistance to Nutlin-3 induced apoptosis [19]. 
Furthermore, the reduced sensitivity of S-type cells to 
RG7388 compared to N-type (neuronal) cells is consistent 
with previous reports of different outcomes of S- versus 
N-type neuroblastoma cells in response to p53 activation, 
including Nutlin-3 and MI-63, where N-type cells are 
more likely to undergo apoptosis in contrast to S-type 
cells which undergo a G1 cell cycle arrest [18, 21, 23, 
24]. In response to 10× GI50 concentrations of RG7388, 
the one predominantly S-type (S>N) and all the N-type 
neuroblastoma cell lines tested in the present study 
demonstrated increased caspase 3/7 activity, whereas 
S-type SKNRA cells did not. 
The difference between the mean RG7388 GI50 
concentrations of MYCN amplified versus non-amplified 
cell lines was not statistically significant, in contrast to 
our previous study with Nutlin-3 and MI-63 [18] but 
consistent with another [19]. However, in line with 
Gamble et al [18], sensitivity of MYCN non-amplified 
neuroblastoma cell lines to RG7388 were more varied 
compared with MYCN amplified cell lines. In the isogenic 
system, however, Tet21N MYCN+ cells were significantly 
more sensitive to RG7388, as well as to other structurally 
diverse MDM2-p53 antagonists, namely, NDD0005, MI-
63 and Nutlin-3a, compared with Tet21N MYCN- cells. 
This result is consistent with previous studies of Nutlin-3 
and MI-63 in this paired cell line [18, 25], and the greater 
sensitivity of Tet21N MYCN+ cells to chemotherapy [26]. 
Increased sensitivity of Tet21N cells to RG7388 and other 
MDM2-p53 antagonists in the presence of MYCN, may 
be explained by our previous observations that p53 is a 
direct transcriptional target of MYCN [20]. Consistent 
with this, the present study demonstrated higher basal p53 
levels in Tet21N MYCN+ cells, as previously reported 
[20]. Furthermore, in response to RG7388 treatment there 
was greater p53 stabilisation and induction of PUMA 
compared with Tet21N MYCN- cells, despite being 
treated with a lower concentration of RG7388. MDM2 
has also previously been reported as a direct target gene of 
MYCN [27], however we did not observe any difference 
in RG7388 sensitivity between MYCN and MDM2 co-
amplified versus MYCN amplified cell lines in the present 
study, in contrast to Gamble et al [18].
RG7388 induced cell cycle arrest and/or apoptosis 
in all p53 wt neuroblastoma cell lines tested, and in 
most cases induction of apoptosis demonstrated by an 
increase in caspase 3/7 activity and sub-G1 events in a 
concentration-dependent manner. Cell cycle arrest was 
not always accompanied by induction of apoptosis, and 
overall, a higher concentration of RG7388 was required to 
induce apoptosis compared to a G1 arrest, consistent with 
previous observations and the p53 apoptotic threshold in 
p53 wt tumour cells [17, 28]. MYCN amplified cell lines, 
LAN5 and IMR32, were the only cell lines which did not 
demonstrate a ≥ 2-fold increase in G1:S ratios, indicative 
of a G1 cell cycle arrest, in response to treatment with at 
least one or more concentrations of RG7388. This latter 
result is in part consistent with our previous observations 
of a failure of MYCN amplified cell lines to undergo G1 
arrest following irradiation-induced DNA damage [29]; 
however, this did not extend to the MDM2 and MYCN 
co-amplified cell lines NGP and NB1691 as a ≥ 2-fold 
increase in G1:S ratio was observed. 
Despite evidence of single-agent activity, the 
development of resistance mechanisms may ultimately 
limit the efficacy of MDM2-p53 antagonists given alone 
[12]. Most likely, MDM2-p53 antagonists will be used in 
combination, initially with existing chemotherapies and/
or radiotherapy, and then with other novel targeted agents. 
The ideal combinations should lead to synergistic cancer 
cell killing while reducing the toxicity associated with 
intensive chemotherapy regimens presently used, which 
is particularly important in young children. To this end, 
the present study assessed whether RG7388 synergises 
with 5 chemotherapy agents most commonly used 
during frontline treatment at diagnosis or relapse, namely 
cisplatin, doxorubicin, topotecan (induction), busulfan 
(consolidation) and temozolomide (relapse) in 5 p53 wt 
neuroblastoma cell lines.
In particular, cisplatin is associated with 
nephrotoxicity and ototoxcitiy, topotecan and doxorubicin 
are associated with significant myelosuppression and 
high-dose doxorubicin with cardiotoxicity. Temozolomide 
is used in a refractory/relapsed disease setting, and 
high-dose busulfan is presently given with high-dose 
melphalan followed by autologous haematopoietic 
stem cell rescue in the consolidation phase of high-risk 
neuroblastoma treatment, and is associated with significant 
non-haematological side-effects including liver (veno-
occlusive disease) and lung toxicity [30]. Overall, the 
majority of RG7388 and chemotherapy combinations 
ranged from slightly synergistic to synergistic in line with 
CI values observed by previous studies of Nutlin-3 and 
chemotherapy, in other cancer types [31, 32]. In most 
cases, combination treatment led to greater stabilisation 
of p53 and increased apoptosis, as evident by higher 
levels of caspase-3/7 activity compared to either agent 
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alone. Furthermore, analysis of CI values against caspase 
3/7 activity of combination treatments demonstrated a 
significant correlation between increased synergy and 
increased apoptosis (Spearman’s Correlation, P < 0.0001) 
in SHSY5Y and NGP cells (Supplementary Figure 5).
Taking into consideration the toxicity profiles of 
the chemotherapeutics tested, and the reported cytopenias 
associated with RG7112/RG7388, the most rational and 
clinically relevant combinations of RG7388 are with 
temozolomide or busulfan. We propose that following 
Phase I evaluation of RG7388 alone, it is tested alongside 
a temozolomide backbone in a randomised Phase II setting 
possibly as an additional arm of the BEACON trial (www.
clinicaltrials.gov; NCT01114555). In addition, RG7388 
could be combined with lower than currently used doses 
of busulfan to try and reduce the non-haematological dose-
limiting toxicities of busulfan, such as veno-occlusive 
disease of the liver and lungs [30]. Here myelosuppression 
is not a concern as busulfan is given immediately prior to 
autologous haematopoietic stem cell rescue. 
Future in vivo studies to support observations of the 
present in vitro study, including dosing and scheduling, 
will need to be conducted in appropriate in vivo models 
of both efficacy and toxicity prior to clinical evaluations 
of RG7388 in neuroblastoma patients. For MDM2-p53 
antagonists murine transgenic models may not be 
suitable as despite a high degree of homology between 
human and mouse MDM2 [33], MDM2-p53 antagonists 
display interspecies selectivity, with reduced binding 
affinities for mouse and rat MDM2 [34, 35]. Consistent 
with this, we have observed that cell lines derived from 
MYCN transgenic mice are less sensitive to MDM2-p53 
antagonists than human neuroblastoma cell lines (Chen et 
al, manuscript in preparation). 
In conclusion, the current study is the first to report 
the highly potent anti-tumour in vitro activity of RG7388 
in p53 wt neuroblastoma cells as a single agent, and 
synergistic activity with conventional chemotherapies 
routinely used to treat neuroblastoma patients. This 
data supports the clinical evaluation of RG7388 alone 
or in combination, in particular with temozolomide or 
busulfan, as a novel therapeutic strategy to potentially 
improve survival and/or reduce toxicity of patients with 
neuroblastoma. The presence of wt p53 remains the most 
robust predictive biomarker of response to RG7388, 
however MYCN, MDM2 and p14ARF status should also 
be recorded. Further identification and validation of non-
invasive, reliable pharmacodynamic proof-of-mechanism 
tumour biomarkers of response to RG7388 are also 
necessary to support the clinical evaluation of this class of 
novel inhibitors in children with neuroblastoma. 
MATERIALS AND METHODS
Chemicals
RG7388 was provided by Hoffman-La Roche 
(Nutley, NJ, USA) [6]. Nutlin-3a was purchased from 
Cambridge Bioscience Ltd (Cambridge, UK). MI-63 
and NDD0005 were synthesised as previously described 
[36, 37]. Cisplatin (Merck Millipore, Watford, UK) was 
dissolved in dimethylformamide (DMF). Doxorubicin, 
topotecan, temozolomide and busulfan (Sigma-Aldrich, 
Dorset, UK) were dissolved in dimethyl sulfoxide 
(DMSO). 
Cell lines
Human neuroblastoma cell lines used and their 
MYCN, p53, MDM2 and p14ARF genetic status are listed 
in Table 1. N_N20R1 and N_M5R1 were generated from 
parental NGP cells with resistance to 20 µM Nutlin-3 or 
5 µM MI-63, respectively. Both cell lines harbour p53 
point mutations at codon 152 (exon 5) with N_M5R1 
having a second point mutation at codon 176 (exon 5), 
and N_N20R1 having a second mutation at codon 98 
(exon 4) (J. Lunec, unpublished). All neuroblastoma cell 
lines were obtained between 1996 and 2007 and were 
validated upon receipt using cytogenetic analysis courtesy 
of Dr Nick Bown (Institute of Human Genetics, Newcastle 
University), and maintained as previously described [38]. 
To switch off MYCN, Tet21N cells were cultured in the 
presence of 1 μg/mL of tetracycline (Sigma) for at least 
24 hours. p53 wt, MDM2 amplified human osteosarcoma 
SJSA-1 cells obtained from the ATCC were cultured 
in RPMI-1640 supplemented with 10% (v/v) FCS. 
Photomicrographs were captured using a VisiCam® 
digital camera and analyser software (VWR International 
Ltd, Lutterworth, UK). 
Growth inhibition assays and Median-effect 
analysis
Seventy-two hour growth inhibition assays and 
GI50 concentration determination were performed as 
previously described [38]. For combination studies, cells 
were treated for 72 hours with RG7388 and conventional 
chemotherapies alone and in combination simultaneously 
at constant 1:1 ratios of 0.25×, 0.5×, 1×, 2× and 4×, or 
0.125×, 0.25×, 0.5×, 1× and 2×, their respective GI50 
concentrations, depending on the drug solubility. Median-
effect analysis and Combination Index (CI) values were 
determined using CalcuSyn v2 (Biosoft, Cambridge, UK). 
Experiments were at least n=3. 
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Western blotting
Western analysis was carried out as previously 
described [38]. Primary antibodies used were p53 1:1000 
(NCL-L-p53-DO7, Leica Biosystems Ltd, Newcastle 
upon Tyne, UK), MYCN 1:500 (sc-53993, Santa Cruz 
Biotechnology Inc., Dallas, TX, USA), MDM2 1:200 
(OP46, Merck), p21WAF1 1:200 (OP64, Merck), p53 
upregulated modulator of apoptosis (PUMA) 1:500 
(ab9643, Abcam, Cambridge, UK) and GAPDH 1:500 
(sc-25778, Santa Cruz). Experiments were at least n=3.
Flow cytometry 
Cells were harvested at the indicated times post-
treatment, fixed in ice-cold 70% (v/v) ethanol and stored 
at -20°C. Prior to analysis, cells were washed with PBS, 
resuspended in 500 µL PBS with 50 µg/mL propidium 
iodide (Sigma) and 50 µg/mL RNAse A (Sigma), and 
incubated at 37°C for 30 minutes. Samples were analysed 
on the FACSCaliburTM using CellQuest Pro software 
(Becton Dickinson, Oxford, UK). Data were analysed 
using Cyflogic (CyFlo Ltd, Turku, Finland). Experiments 
were at least n=3.
Caspase 3/7 assays
Caspase-3/7 activity was assayed using Caspase-
Glo 3/7 assay (Promega, Southampton, UK) according to 
the manufacturer’s instructions. Experiments were at least 
n=3.
Statistical analyses
All statistical tests were performed using GraphPad 
Prism v6.0 software and P < 0.05 taken to be the level of 
statistical significance. 
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